Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
228.18B
Market cap228.18B
Price-Earnings ratio
14.16
Price-Earnings ratio14.16
Dividend yield
2.49%
Dividend yield2.49%
Average volume
31.49M
Average volume31.49M
High today
$50.53
High today$50.53
Low today
$48.95
Low today$48.95
Open price
$50.06
Open price$50.06
Volume
15.85M
Volume15.85M
52 Week high
$93.80
52 Week high$93.80
52 Week low
$43.08
52 Week low$43.08

NVO News

Nasdaq 2h
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore

Key Points Viking Therapeutics is advancing weight loss candidates through phase 2 and phase 3 trials. Results so far have been very promising. 10 stocks we...

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore
TipRanks 21h
Canaccord cuts Hims & Hers target, says legal risk may be priced in

Canaccord lowered the firm’s price target on Hims & Hers (HIMS) to $30 from $68 and keeps a Buy rating on the shares after Novo Nordisk (NVO) filed a lawsuit ag...

TipRanks 21h
Novo Nordisk Discloses Executive Share Sale to Cover Tax on Long-Term Incentive Shares

Novo Nordisk ( (NVO) ) has issued an announcement. On 9 February 2026, Novo Nordisk Executive Vice President for R&D and Chief Scientific Officer Martin Holst...

Analyst ratings

53%

of 34 ratings
Buy
52.9%
Hold
35.3%
Sell
11.8%

More NVO News

Sherwood News 22h
Hims built a boundary-pushing health business. Now the legal risks are catching up.

Hims is close to trading as if it never began selling GLP-1s. Hims & Hers aired its second Super Bowl commercial on Sunday, questioning a healthcare system it...

Hims built a boundary-pushing health business. Now the legal risks are catching up.
TipRanks 1d
‘Blatant Attack’: HIMS Stock Plunges as Novo Lawsuit Triggers Analyst Price Target Cuts

Shares of Hims & Hers Health (HIMS) fell about 16% on Monday, extending last week’s losses following a regulatory crackdown on its non-FDA-approved compounds. T...

Simply Wall St 1d
Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside

Novo Nordisk (NYSE:NVO) has filed a lawsuit against Hims & Hers, alleging patent infringement tied to compounded oral semaglutide products. The case centers on...

Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside
The Motley Fool 1d
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny. Expand NYSE : HIMS Hims...

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit
Nasdaq 1d
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?

Key Points On Friday, the U.S. Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 ingredients in compounded drugs not approved...

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Cheddar 2d
Novo Nordisk Sues Hims Over Copycat Wegovy

Novo Nordisk is suing telehealth company Hims & Hers, accusing it of illegally mass marketing cheaper, unapproved compounded versions of Wegovy....

Novo Nordisk Sues Hims Over Copycat Wegovy
Nasdaq 2d
Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?

Key Points Eli Lilly has been a growth beast and its top line may soar by as much as 27% this year. Novo Nordisk is bracing for a potential double-digit decli...

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.